Azelastine Nasal Spray Dosing and Use in Children 6–11 Years

FDA‑Approved Dosing

• The American Academy of Otolaryngology‑Head and Neck Surgery states that children aged 6–11 years should receive 1 spray per nostril twice daily of azelastine nasal spray. 1
• The same dosing (1 spray per nostril twice daily) applies regardless of whether the 0.1 % or 0.15 % formulation is used. 1

Approved Formulations

• Azelastine 0.1 % (Astelin) delivers approximately 137 µg of drug per spray and is approved for seasonal allergic rhinitis and vasomotor rhinitis in children ≥ 6 years. 1
• Azelastine 0.15 % (Astepro) delivers approximately 205.5 µg of drug per spray and is approved for both seasonal and perennial allergic rhinitis in children ≥ 6 years. 1

Efficacy and Therapeutic Role

• Clinical data indicate that azelastine nasal spray effectively relieves nasal congestion, an outcome that oral antihistamines address poorly. 1
• The spray can be employed as either first‑line or second‑line therapy for allergic rhinitis in the pediatric population. 1

Common Adverse Effects (Counseling Points)

• The most frequently reported side effect is a bitter taste, which may affect adherence. 1
• Epistaxis (nosebleed) is another commonly observed adverse event. 1
• Somnolence occurs in approximately 0.4–3 % of children, a rate comparable to placebo. 1
• Headache has also been reported as a side effect. 1

Compliance Considerations

• Taste aversion is the primary barrier to compliance; if a child experiences significant bitterness with one concentration, switching to the alternative formulation (0.1 % ↔ 0.15 %) or to a newer formulation containing sorbitol and sucralose may improve tolerability. 1

Indications for Use in Children

• Azelastine is advantageous for episodic nasal symptoms because of its rapid onset of action (effects within minutes). 1
• It can be used as pretreatment before anticipated allergen exposure to mitigate symptom development. 1
• The spray is recommended for children who have not achieved adequate control with oral antihistamines. 1
• It offers targeted nasal delivery with limited systemic absorption, making it suitable for pediatric patients requiring localized therapy. 1

Rapid‑Onset Efficacy and Therapeutic Role of Azelastine in Pediatric Allergic Rhinitis

Rapid Onset of Action

• In children with seasonal allergic rhinitis, a single dose of azelastine nasal spray (0.1 % formulation) produces clinically significant symptom relief within 15 minutes, making it useful for episodic symptoms or pretreatment before anticipated allergen exposure. 2

Adverse‑Effect Profile

• Approximately 20 % of pediatric patients report a bitter taste after azelastine administration, which is the most frequently observed side effect. 2

Sedation and Performance Impact

• Azelastine demonstrates minimal sedation, with somnolence rates comparable to placebo and no significant impairment of performance in children, unlike first‑generation oral antihistamines. 2

Comparative Effectiveness with Intranasal Corticosteroids

• Intranasal corticosteroids provide greater overall symptom control than azelastine for allergic rhinitis, although azelastine offers a faster onset of relief. 2

Position in Treatment Algorithms for Moderate‑to‑Severe Disease

• For moderate‑to‑severe allergic rhinitis in children, intranasal corticosteroids are recommended as first‑line therapy, while azelastine should be reserved for breakthrough symptoms or situations requiring rapid symptom relief. 2